The QualityStocks Daily Friday, April 21st, 2023

Today's Top 3 Investment Newsletters

QualityStocks(ONTX) $1.0900 +55.49%

MarketClub Analysis(PRST) $3.6100 +36.23%

Schaeffer's(MULN) $0.1029 +21.49%

The QualityStocks Daily Stock List

Onconova Therapeutics (ONTX)

MarketBeat, TraderPower, PCG Advisory, BUYINS.NET, StreetInsider, StockMarketWatch, QualityStocks, The Street, Channelchek, Broad Street, AwesomeStocks, Penny Stock 101, StockRockandRoll, OTCBB Journal, PennyStockLocks, The Online Investor, Investors Alley, MarketClub Analysis,, Money Morning, SeeThruEquity Research, Schaeffer's, InvestorPlace, Investing Futures, Daily Trade Alert, Zacks, TopPennyStockMovers, Trades Of The Day and Louis Navellier reported earlier on Onconova Therapeutics (ONTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Onconova Therapeutics Inc. (NASDAQ: ONTX; FRA: OT22) is a biopharmaceutical firm which operates through the discovery and development of oncology therapeutics. Onconova is centered on finding and developing drug candidates to fight cancer.

The firm has its headquarters in Newton, Pennsylvania and was founded on December 22, 1998 by E. Premkumar Reddy and Ramesh Kumar. Onconova launched its IPO in 2013, which generated $78 million.

Onconova Therapeutics has various revenue-generating collaboration agreements with different companies. These include its collaboration and license agreement with HanX Biopharmaceuticals, a commercialization, development and license agreement with Pint International SA, and a SymBio Pharmaceuticals limited license agreement, for the registration, development and marketing of ON 123300.

Onconova Therapeutics Inc. has developed anti-cancer agents that work against particular cellular pathways vital to cancerous cells. The company’s drug candidates include both oral and intravenous formulations Rigosertib, which are in their Phase 2 and 3 clinical trials for lower and higher risk myelodysplastic syndromes as well as head, neck and pancreatic cancers. It’s other candidate Briciclib is undergoing a phase 1 dose-escalation multi-site trial for advanced solid tumors. Another drug candidate developed by the firm, Recilisib, recently concluded 4 phase 1 clinical trials for acute radiation syndromes.

The firm is focused on developing medications that better the outcomes of cancer patients, addresses the recurrence of the ailment and reduces the side effects brought about by the current cancer treatment methods. Rigosertib, which is Onconova’s lead candidate, has shown potential in doing so. If the product demonstrates promising results in its clinical trials, which result in an effective treatment, it may revolutionize how cancer, a disease that so many individuals succumb to annually, is managed and treated.

Onconova Therapeutics (ONTX), closed Friday's trading session at $1.09, up 55.4922%, on 23,343,375 volume. The average volume for the last 3 months is 14.618M and the stock's 52-week low/high is $0.62/$1.55.

Solar Integrated Roofing (SIRC)

MoneyTV, TopPennyStockMovers, Wall Street Mover, InvestorPlace, QualityStocks, Profitable Trader Authority, PoliticsAndMyPortfolio, AllPennyStocks, OTCtipReporter, Planet Penny Stocks, Buzz Stocks, DSR News, PHUB News, Small Cap Firm, SmallCapVoice and PennyStockScholar reported earlier on Solar Integrated Roofing (SIRC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Solar Integrated Roofing Corp (OTC: SIRC) is an integrated single-source solar power, roofing and HVAC (heating, ventilation and air conditioning) systems installation firm.

The firm has its headquarters in El Cajon, California and was incorporated in 2007, on May 1st by Dave Massey. Prior to its name change in November 2015, the firm was known as Landstar Development Group Inc. The firm serves consumers in the United States.

The company specializes in residential and commercial property development, joint venture partnerships, government land use, land banking, home building and water & sewer utility construction and operations. It serves communities by delivering the best experience through legacy-focused leadership and constant innovation.

The enterprise’s broad array of solutions includes solar energy battery systems, battery backup and electric vehicle charging stations to HVAC, roofing and related electrical contracting work. Its projects include Willowcrest Condos, Tuscan Hills, the Vineyards, LTV Plaza, Hacienda Heights and Desert Willows. The enterprise provides its services to residential and commercial properties and facilities through the following brands: SunUp Solar, Cornerstone Construction, Approved Home Pros, Enerev Solar, USA Solar Networks, PLEMCo, Secure Roofing and Solar, Future Home Power, SunPower by Milholland Electric, Balance, McKay Roofing Co. and Montross Companies.

The firm, which has made a number of high-margin acquisitions, recently reported its latest financials that show significant increases in its revenue. It is focused on generating more shareholder value and the integration of its acquired companies, which will allow it to capture the full revenue lifecycle of its consumers.

Solar Integrated Roofing (SIRC), closed Friday's trading session at $0.0281, up 21.1207%, on 14,617,955 volume. The average volume for the last 3 months is 3.429M and the stock's 52-week low/high is $0.0134/$0.615.

Netlist, Inc. (NLST)

Greenbackers, OTCPicks, StreetInsider, QualityStocks, HotOTC, CoolPennyStocks, StockEgg, BullRally, MarketBeat, PennyTrader Publisher, PennyInvest, PennyStockVille, StockRich, MadPennyStocks, MarketClub Analysis, Wall Street Resources,, CRWEWallStreet, TopPennyStockMovers, Stock Rich, MicrocapVoice, Momentum Traders, Stock Traders Chat, StockMarketWatch, StockOodles, The Street, BUYINS.NET, TradersPro, Trading Concepts, Wyatt Investment Research, DrStockPick, CRWEPicks, CRWEFinance, BestOtc, Penny Invest, Penny Sleuth, SmallCapNetwork, AllPennyStocks, PennyOmega, PennyToBuck, PennyTrader, Penny Stock Rumble, Stockpalooza, StockHotTips, Dividend Opportunities, StockMister, The Momentum Traders Network, Top Stock Picks, TradingMarkets, InvestorGuide, Wise Alerts, Barchart, Alternative Energy, TopStockAnalysts, Dynamic Wealth Report, Stock Fortune Teller, PennyStocks24, SmarTrend Newsletters, Investors Alley, SmallCapVoice, SmallCapReview, PoliticsAndMyPortfolio, MarketWatch, MicroCapINPLAY, Momentum Trades, Zacks and Hit and Run Candle Sticks reported earlier on Netlist, Inc. (NLST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Netlist, Inc. provides high-performance SSDs and modular memory subsystems to enterprise customers in diverse industries. The Company’s NVMe™ SSD portfolio provides industry-leading performance offered in numerous capacities and form factors. Netlist holds a portfolio of patents in the areas of server memory, hybrid memory, storage class memory, rank multiplication, and load reduction. Founded in 2000, Netlist is based in Irvine, California.

In essence, Netlists is a leading provider of high-performance modular memory subsystems to the world’s premier (Original Equipment Manufacturers) OEMs. The Company specializes in hybrid memory – the merging of DRAM and NAND flash raw materials to create memory solutions. Its patented memory technologies provide premier performance, and high density in a cost efficient solution. Netlist serves different industries (from database to enterprise applications) that require superior memory performance to enable critical business decisions in today’s data-driven environment.

HybriDIMM™, Netlist's next-generation storage class memory product, addresses the growing requirement for real-time analytics in Big Data applications, in-memory databases, high-performance computing, and advanced data storage solutions. Furthermore, the Company manufactures a line of specialty and legacy memory products to storage customers, appliance customers, system builders, and cloud and datacenter customers.

Netlist, Inc. (NLST), closed Friday's trading session at $4, up 21.2121%, on 3,429,227 volume. The average volume for the last 3 months is 800 and the stock's 52-week low/high is $0.8701/$6.65.

VentriPoint Diagnostics (VPTDF)

QualityStocks, FeedBlitz, The Howard Group, UndiscoveredEquities, SmallCap Network and Greenbackers reported earlier on VentriPoint Diagnostics (VPTDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

VentriPoint Diagnostics Ltd (OTCQB: VPTDF) (CVE: VPT) (FRA: 5V7) is a medical device firm that is focused on the development and commercialization of diagnostic tools that monitor patients with heart disease.

The firm has its headquarters in Toronto, Canada and was incorporated in 2005, on May 4th by Florence H. Sheehan and Joseph Ashley. It operates as part of the medical devices industry, under the healthcare sector. The firm serves consumers around the globe.

The company is dedicated to developing quality, smart tools that help solve the immediate needs of healthcare clinicians and most importantly improves the clinical experience for the youngest to the oldest patient. It uses images acquired with devices already in use to create three-dimensional models and critical measurements.

The enterprise’s offerings include the Ventripoint Medical System (VMS), a medical imaging system that is used to generate 3D models with critical volume and functional measurements of a patient's heart chambers; and the VMS+ software, which is used to create 3D models of the heart chamber using echocardiograms and magnetic resonance imaging images. This system also generates reproducible, accurate volumetric measurement, and ejection fraction. Its VMS products are powered by its proprietary KBR technology. The enterprise also develops a suite of applications for various heart diseases and imaging modalities, including pulmonary hypertension, congenital heart disease, cardiotoxicity in oncology patients, and coronavirus-related heart issues.

The firm recently provided a corporate update, with its CEO noting that they remained focused on driving accelerated sales growth. This will bring in additional revenues into the firm while also creating shareholder value.

VentriPoint Diagnostics (VPTDF), closed Friday's trading session at $0.136, even for the day. The average volume for the last 3 months is 7.399M and the stock's 52-week low/high is $0.1208/$0.29507.

Hanesbrands (HBI)

Mesh Money, MarketClub Analysis, InvestorPlace, Kiplinger Today, Schaeffer's, StocksEarning, The Street, MarketBeat, Barchart, Daily Trade Alert, Zacks, StreetAuthority Daily, The Online Investor, StreetInsider, Louis Navellier, Stock Gumshoe, TheStockAdvisors, Trades Of The Day, Market Report, SmarTrend Newsletters, Top Pros' Top Picks,, Uncommon Wisdom, Wealth Insider Alert, Market Intelligence Center Alert, TopStockAnalysts, StockEarnings, Dividend Opportunities, Trading Concepts, Coattail Investor, Investing Daily, Daily Markets, BUYINS.NET, The Wall Street Transcript, Wyatt Investment Research, Money Morning, Trading Tips, Early Bird, Dynamic Wealth Report, The Night Owl, Daily Wealth, The Trading Report, 24/7 Trader, TheStreet Offers, Greenbackers, CNBC Breaking News, TradingMarkets, AllPennyStocks, Daily Profit, FreeRealTime, Money and Markets, The Best Newsletters, Insider Wealth Alert, Stock Up Featured, Investing Signal, Investment House, Investopedia, Short Term Wealth, InvestorsObserver Team, One Hot Stock, Money Wealth Matters, Market FN and FNNO Newsletters reported earlier on Hanesbrands (HBI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hanesbrands Inc. (NYSE: HBI) (LON: 0J2X) (FRA: HN9) (BVMF: H1BI34) is a consumer goods firm that is focused on designing, manufacturing, sourcing and selling a range of basic apparel for women, men and children.

The firm has its headquarters in Winston-Salem, North Carolina and was incorporated in 1901 by J. Wesley Hanes. It operates as part of the apparel manufacturing industry, under the consumer cyclical sector. The firm serves consumers around the globe, with a primary focus on those in the State of North Carolina, U.S.

The enterprise operates through the Activewear, Innerwear and International segments. Its products include intimate apparel, such as bras and shapewears, as well as women’s panties, men's underwear, children's underwear and socks. It also sells activewear; home goods; and fleece, T-shirts, sport shirts, performance apparel, sports bras, performance T-shirts and shorts, thermals and teamwear. This is in addition to selling licensed logo apparel in collegiate bookstores and mass retail channels. The enterprise licenses its Champion name for footwear and sports accessories. It offers its products primarily under the Hanes, Maidenform, Champion, Bali, JMS/Just My Size, Playtex, Polo Ralph Lauren, Alternative, Comfortwash, Gear for Sports, Bonds, Hanes Beefy-T, Wonderbra, Bras N Things, Sheridan, Rinbros, Bellinda, Berlei, Zorba, Maidenform and Sol y Oro brand names. The enterprise markets its products through wholesalers, retailers and third-party embellishers.

The company recently launched the New Hanes Originals campaign, which brings to life a unique view of comfort. This will encourage consumers to embrace current styles without sacrificing their comfort and in turn, bring in additional revenues into the company.

Hanesbrands (HBI), closed Friday's trading session at $4.96, up 1.2245%, on 7,399,182 volume. The average volume for the last 3 months is 486,435 and the stock's 52-week low/high is $4.73/$14.90.

Micromem Technologies (MMTIF)

QualityStocks, OurHotStockPicks, Xtremepicks, PennyStocks24, Stock Stars and SmallCapVoice reported earlier on Micromem Technologies (MMTIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Micromem Technologies, Inc. (OTCQB: MMTIF) (CNSX: MRM) is a company focused on designing, developing and providing customized sensor applications based on its proprietary technology.

The firm has its headquarters in Toronto, Canada and was incorporated in 1985, on October 21st. Prior to its name change in January 1999, the firm was known as Avanti Corp International Inc. It operates as part of the semiconductors industry, under the technology sector. The firm serves consumers around the globe, with a focus on those in Canada.

The company is a leader in viable Sensor Technology and has held patents for over twenty years claiming priority in various applications. It works with various clients including Castrol, Repsol, Chevron, Romgaz, Entanglement Technologies, eCamion and Eversource Energy.

The enterprise’s applications include structural integrity solutions, oil sensor solutions, nanoparticle detection solutions, and energy storage solutions. Its oil sensor solutions include AROMA tracer detection commercialized product, MEMS sensor system for real time wear analysis, integrated oil pan plug analysis system and power transformer oil degradation sensor. Its nanoparticle detection solutions include a nanoscale fracking sensor and a magnetic nanoparticle detection platform. Its structural integrity solutions include corrosion detection solution and powerline monitoring, and a cement integrity sensor solution. The enterprise has also developed a miniaturized laser-induced breakdown spectroscopy (LIBS) prototype device based on its fluorescent nanoparticle detection technology and its MEMS capabilities.

The company remains committed to building its expertise and to better meet consumer needs globally, which will bring in additional revenues into the company while also creating value for its shareholders.

Micromem Technologies (MMTIF), closed Friday's trading session at $0.125, even for the day, on 486,435 volume. The average volume for the last 3 months is 375 and the stock's 52-week low/high is $0.025/$0.1478.

Fire & Flower (FFLWF)

We reported earlier on Fire & Flower (FFLWF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fire & Flower Holdings Corp. (OTCQX: FFLWF) (TSE: FAF) is an independent cannabis retailer focused on the sale of marijuana products.

The firm has its headquarters in Toronto, Canada and was incorporated in 2017, on December 12th. It operates as part of the pharmaceutical retailers industry, under the healthcare sector. The firm serves consumers in Canada and the United States.

The company operates through the Wholesale & Logistics, Retail, Digital Platform, and Corporate segments. The Wholesale & Logistics segments is focused on distributing and delivering cannabis products while the Retail segment is focused on providing cannabis products and accessories to the adult-use market in provinces where the sale of cannabis is legal. On the other hand, the Digital Platform segment comprises of products and services offered by the Hifyre digital and analytics platform, CannDeliv logistics platform and PotGuide content platform. The company generates most of its revenue from the retail segment.

The enterprise sells and distributes cannabis products and accessories to the adult-use market through private retailers, as well as under the Fire & Flower, Happy Dayz, Friendly Stranger and Hotbox retail banners. It also operates the Spark Perks customer loyalty program; cannabis websites and content platforms under the Wikileaf names; and Pineapple Express, a delivery platform. The enterprise operates and owns cannabis retail stores in the provinces of Alberta, British Columbia, Ontario, Manitoba, Saskatchewan and the Yukon territory.

The firm recently launched the Spark Marketplace mobile app on the App Store for iPhones, a move that will simplify consumer shopping experiences while also extending its reach.

Fire & Flower (FFLWF), closed Friday's trading session at $1.01, off by 1.9417%, on 375 volume. The average volume for the last 3 months is 5,801 and the stock's 52-week low/high is $0.6959/$3.62.

Marks & Spencer (MAKSF)

We reported earlier on Marks & Spencer (MAKSF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marks and Spencer Group PLC (OTCQX: MAKSF) (LON: MKS) (FRA: MA6) (BMV: MKSN) is a retail company that is engaged in the retail of clothes, food, and home products.

The firm has its headquarters in London, the United Kingdom and was incorporated in 1884, on September 28th by Thomas Spencer and Michael Marks. It operates as part of the department stores industry, under the consumer cyclical sector. The firm primarily serves consumers in the United Kingdom.

The company operates through the UK Clothing and Home, International, UK Food, Ocado and All Other segments. The UK Clothing and Home segment is focused on retailing menswear, womenswear, kidswear, lingerie and home products. The International segment is comprised of Marks and Spencer owned businesses in Asia and Europe and the global franchise operations. The UK Food segment includes the results of the UK Food franchise and UK retail food business operations. On the other hand, the Ocado segment represents the company's share of profits or losses from the investment in Ocado Retail Ltd. The All Other segment covers other business activities and operating segments, including M&S Energy and M&S Bank.

The enterprise provides protein deli and dairy; ambient and in-store bakery; produce; meals dessert and frozen; and hospitality and ‘Food on the Move’ products. It also offers financial services, including credit cards, insurance, payment solutions, loans and savings; and renewable energy services. In addition to this, the enterprise invests in and develops real estate properties.

The firm recently announced plans to increase the number of third-party brands it sells, in a bid to increase its sales and extend its consumer reach.

Marks & Spencer (MAKSF), closed Friday's trading session at $2.1, even for the day. The average volume for the last 3 months is 2,200 and the stock's 52-week low/high is $1.02/$2.10.

Reunion Gold Corporation (RGDFF)

MarketBeat reported earlier on Reunion Gold Corporation (RGDFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Reunion Gold (TSX.V: RGD) (OTC: RGDFF) is reporting on additional drill results from its wholly owned Oko West Project in Guyana. According to the company, the results continue to confirm the grade and continuity of the Kairuni zone, and Reunion Gold continues to explore further zones along strike. Specifically, the report showed that holes D-213, D-234 and D-243 confirm the presence of higher-grade mineralized “shoots” within block 4, which have been identified from previous drill results. According to the report, these higher-grade shoots remain open at depth, below the extent of drilling completed to date. In addition, initial results from Scout RC geochemical program on the western portion of the Oko West Prospecting License revealed several targets for follow-up drilling, and progress is being made on advancing and derisking the project. The drill program, which is part of an approximately 30,000-meter drill plan, was initiated at the beginning of this year. “We are advancing our Oko West project along two tracks,” said Reunion Gold president and CEO Rick Howes in the press release. “The first is to advance the exploration programs outside of the Kairuni zone, aimed at outlining and discovering additional gold mineralization within our Prospecting License. On this front, I am very excited by the results from the initial Scout RC Geochem drill program that is defining new targets west of our Kairuni zone. The second track is continuing to advance the Kairuni zone along the path to development as quickly as possible. We are currently on schedule to announce our Maiden Resource Estimate by the middle of the year, to be followed by the commencement of a PEA with targeted completion by year-end 2023.”

To view the full press release, visit

About Reunion Gold Corporation

Reunion Gold Corporation is a leading gold explorer in the Guiana Shield, South America. In 2021 the company made an exciting new gold discovery at its Oko West project in Guyana, where to date it has outlined continuous gold mineralization at the Kairuni zone over 2,000 meters of strike and to a depth of 600 meters. The mineralization appears to be open-pit amenable with a strong grade profile. In addition to Kairuni, there are several additional priority exploration targets on the Oko West project area that the company is exploring. For more information about the company, please visit

Reunion Gold Corporation (RGDFF), closed Friday's trading session at $0.334725, up 1.4318%, on 2,200 volume. The average volume for the last 3 months is 189,925 and the stock's 52-week low/high is $0.163/$0.36.

Compass Pathways PLC (CMPS)

InvestorBrandNetwork, QualityStocks, InvestorPlace, MarketBeat, Daily Trade Alert, StreetInsider, Schaeffer's, Trades Of The Day and The Street reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

We have seen interest in psychedelics increase significantly these last few years, with more studies highlighting the medical benefits these substances possess. Thus far, research has shown that psychedelics such as psilocybin, MDMA and ketamine may help treat mental health conditions, including anxiety, depression, post-traumatic stress disorder and substance-use disorder.

Now, researchers believe that these substances may be useful in the management of long COVID-19 symptoms.

Individuals with long COVID-19 often present with coronavirus symptoms that may last months or even years after the infection. The most common symptoms of long COVID-19 include feeling short of breath, extreme fatigue, muscle aches and loss of smell.

Studies on psychedelics and long COVID aren’t many because psychedelic drugs are still illegal at the federal level, due to their classification as Schedule I substances under the Controlled Substances Act.

But, research is growing, with Dr. Joel Castellanos of the Psychedelics and Health Research Initiative at the University of California-San Diego revealing that he’s heard from many patients with long COVID who have tried psychedelics. Castellanos revealed that one patient who used a psilocybin and MDMA combination to manage their symptoms actually saw improvements in their headaches, fatigue, depression and brain fog.

Dr. Sue Sisley, a psilocybin researcher at Scottsdale Research Institute, has also had patients admit to using psychedelics as long COVID remedies, noting that some did see improvements in their memory, cognitive function and energy. Sisley, who works in a community clinic catering to patients with long COVID, recently advised legislators on a measure that would allocate millions for studies into the therapeutic potential of psilocybin for various conditions, including long COVID.

She believes that psilocybin alleviates symptoms of this condition by encouraging tissue growth and new neuronal connections in the brain and decreasing inflammation in an individual’s body.

Prior studies have suggested that inflammation may be a target for psychedelic treatments. Professor Charles Nichols of pharmacology at the Louisiana State University has discovered, using mouse models, that certain psychedelics have anti-inflammatory effects.

If the same is found to be true in people, Nichols believes that it’s reasonable to think psychedelic drugs could also offer relief to individuals suffering from long COVID-19. It should be noted, however, that at this particular point in time, none of these claims have been proven as no clinical trials have been conducted to ascertain psychedelics’ effectiveness in managing long COVID-19 symptoms.

Individuals are advised to proceed with a lot of caution because psychedelics are potent drugs. This potency is largely the reason why startups such as Compass Pathways PLC (NASDAQ: CMPS) envisage psychedelic treatments being administered in clinical settings only.

Compass Pathways PLC (CMPS), closed Friday's trading session at $8.96, off by 5.5848%, on 189,925 volume. The average volume for the last 3 months is 13.172M and the stock's 52-week low/high is $6.54/$21.50.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, Schaeffer's, QualityStocks, The Street, StockEarnings, MarketClub Analysis, Early Bird, MarketBeat, StocksEarning, Investopedia, Daily Trade Alert, The Online Investor, Trades Of The Day, INO Market Report, Kiplinger Today, GreenCarStocks, Louis Navellier, The Wealth Report, The Night Owl, AllPennyStocks, The Stock Dork, Green Energy Stocks, Zacks, Wealth Whisperer and InvestorsUnderground reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Prices of lithium have been falling sharply since early this year, meaning that less expensive electric vehicles may be expected in the future. After a two-year surge, the main battery ingredient declined by more than 65% as of January 2023.

In November, the price reached a peak at $85,000, and Jean-Charles Cachon, an analyst from the mining industry, says it’s too high to be sustainable. Currently, this metal is now going for less than $30,000 a metric ton.

Cachon pointed to China’s withdrawal of the electric vehicle subsidies that led to slower sales and a reduction in demand for these environmentally friendly auto alternatives. According to him, this slump in price was triggered when lithium prices that had actually been more than 10 times the production costs went down as a result of China’s slowdown in January.

This isn’t only for lithium: Prices are falling for the rest of the metals used to make batteries, such as nickel and cobalt. As the price of these essential minerals continues to decrease, Daniel Breton says that it’s possible that this slowdown may be advantageous for consumers and that another wave of electric cars selling between $25,000 and $40,000 can be expected as the production of batteries gains momentum in the sector.

In parallel, mining corporations all over the world have seen their profitability squeezed by falling prices. Josée Méthot, CEO of the Quebec Mining Association, stated that even though the industry has been known to see rises and falls in the prices of minerals, some investors will be alarmed. But, according to him, this isn’t a deterrent to anyone who has the ability to understand markets and anticipate future market demand.

Trevor Walker says that right now there is nothing to be afraid of. Despite the current prices on the market, he claims that the manufacture of lithium salts costs approximately $9,000 to $10,000 for each metric ton, so producers are still making a profit.

The high prices of the battery-grade metal are still attractive enough to attract industry participants, large and small, in order to continue with fresh projects. Currently, according to the government of Canada, a total of approximately 3.2 million metric tons of lithium oxide exist at their different mine sites.

As the automotive sector in Ontario begins to make electric cars as well as EV batteries, Walker predicts a growing demand for lithium salts. He has a company that is in the early stages of production but aims to supply automakers.

The public can look forward to more affordable electric vehicles from several manufacturers such as Lucid Motors (NASDAQ: LCID) as the result of dropping raw material prices.

Lucid Motors (LCID), closed Friday's trading session at $7.03, off by 0.565771%, on 13,171,864 volume. The average volume for the last 3 months is 1.578M and the stock's 52-week low/high is $6.09/$21.87.

Stronghold Digital Mining Inc. (SDIG)

QualityStocks, RedChip, MarketBeat, SmallCapVoice, Real Pennies, InvestorPlace, StocksEarning, StockPicksNYC, StockEarnings, OTC Markets Group and Early Bird reported earlier on Stronghold Digital Mining Inc. (SDIG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last year was a torrid year for crypto enthusiasts. The biggest cryptocurrency, Bitcoin, sank by 64%, while Ethereum fell by 67%. The value of Dogecoin, a joke cryptocurrency that later gained popularity among Elon Musk and his supporters, dropped by almost 60%.

In addition, many of the biggest exchanges either collapsed or are still facing legal troubles. The arrest of FTX’s founder, Sam Bankman-Fried, after the company’s collapse in November last year has shifted authorities’ attention to the industry.

However, the first few months of 2023 has seen a dramatic increase in the value of cryptocurrencies, with Bitcoin surging by an astounding 80%. It passed the $30,000 mark last week for the first time since June of last year. Ether and Dogecoin have also increased by 34% and 74%, respectively, since the start of 2023.

What then has caused crypto’s value to increase? One cause is the rising belief among economists this year that the U.S. Federal Reserve is almost done raising interest rates.

Similar to equities, cryptocurrencies are still quite susceptible to changes in interest rates, which is one of the reasons why they took a beating in 2022 after the Fed raised interest rates.

Another contributing factor is the return of market speculators. Last week, Coindesk reported that the proportion of daily Bitcoin trading volumes in spot markets to those in derivative markets had decreased to its lowest level in 11 months, signaling a resurgence of speculation in the cryptocurrency market.

One of the most remarkable aspects of this year’s cryptocurrency surge is how, despite traditional banking system shocks such as Silicon Valley Bank’s failure, cryptocurrencies managed these occurrences without a hitch. These circumstances in some respects contributed to reminding cryptocurrency supporters of the development of digital assets as a substitute for the conventional banking system during a global crisis.

There are more signs to suggest that digital assets will endure. Perhaps the most important of these is the recent revelation that the London Stock Exchange Group (LSEG) will start clearing cryptocurrency derivatives.

Despite this, it is important to note that crypto values have failed to maintain advances after reaching big milestones. For instance, when Bitcoin reached $30,000 last week, it found it difficult to maintain that level.

Additionally, some regulators are openly antagonistic as the industry is under closer global scrutiny. For instance, India’s Reserve Bank has urged for the outlawing of cryptocurrencies, comparing them to a Ponzi scheme.

On that premise, it appears that it will take some time before cryptocurrency valuations reach the peaks they reached in 2021. Nonetheless, industry actors such as Stronghold Digital Mining Inc. (NASDAQ: SDIG) may feel that the worst seems to be behind and they can look forward to a better future.

Stronghold Digital Mining Inc. (SDIG), closed Friday's trading session at $0.9834, off by 1.66%, on 1,577,678 volume. The average volume for the last 3 months is 756 and the stock's 52-week low/high is $0.40/$4.59.

The QualityStocks Company Corner

Progressive Care Inc. (OTCQB: RXMD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: RXMD).

RMXD news indicates that a synergistic tech-healthcarecollaboration with potential to ignite both growth and revenues isin the works

“Restructuring whiz” takes the helm as CEO, board chair

Through technology and proven processes, Progressive Care helpssimplify chaos, improve care and reduce costs

Recent developments bode well for the future of Progressive Care (OTCQB: RXMD). On a mission to snag ever more market share using data managementand analytical tools, the well-established healthcare company might be on the cusp ofbreaking out of slow-growth mode and into rapid expansion. Severalfactors are at play that could prove meaningful for the company andits stakeholders.

Progressive Care Inc. (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through its subsidiaries, Progressive Care provides Third-Party Administration (TPA), data management and analytics, COVID-19 diagnostics and vaccinations, 340B contracted pharmacy services, compounded medications, tele-pharmacy services, dispensing of anti-retroviral medications, medication therapy management (MTM), long-term care facility-targeted prescription medications, and health practice risk management.

The company collaborates with various healthcare organizations such as managed care organizations (MCOs), management services organizations (MSOs), accountable care organizations (ACOs), primary care providers, Medicare Advantage plans, Medicaid, commercial payors, pharmaceutical manufacturers, and distributors to enhance patient and provider engagement while improving the lives of patients with chronic diseases. Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.

Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue. Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and MTM services. The company also provides customized management, patient health risk reviews, and free same- and next-day delivery. Its focus is on complex chronic diseases that require multiyear or lifelong therapy, driving recurring revenue and sustainable growth. Progressive Care’s pharmacy revenue growth stems from its expanding breadth of services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers resulting from its emphasis on higher patient engagement, free delivery to the patient, and clinical expertise.

With licenses in 14 states, Progressive Care is poised for national expansion. The company anticipates revenue growth by signing new contract pharmacy service and data management contracts with 340B-covered entities, expanding data management and analytics services to healthcare organizations, and potential acquisitions.


Progressive Care’s wholly-owned subsidiaries provide services to client organizations and patients.

PharmcoRx Pharmacy

PharmcoRx, a full-service pharmacy, provides a complete healthcare ecosystem with services such as medication therapy management, rapid COVID-19 testing and vaccines, contactless medication delivery, Smart-Pack Unit Dosing packaging, custom compound medications, specialty medications, hospital transition pharmacy services, medication adherence monitoring, medication adherence risk management, and drug cost containment. PharmcoRx Pharmacy is a contracted pharmacy services provider for 340B-covered entities under the 340B Drug Discount Pricing Program.


ClearMetrX, a wholly-owned data management company, offers services that support healthcare organizations across the country. In September 2022, ClearMetrX launched the 340MetrX Platform, a software product developed by ClearMetrX that provides 340B-covered entities with data insights to effectively operate and maximize the benefits of the 340B program. 340MetrX supplies data access and delivers actionable insights that providers and support organizations can use to improve their practices and patient care. Its TPA services include management of wholesale accounts and contract pharmacies, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.

Market Opportunity

According to an industry report by global consulting firm Berkeley Research Group, gross sales across the 340B drug program were valued at $116 billion in 2021 and are projected to grow to $280 billion by 2026, achieving a CAGR of more than 19% over the period.

The 340B drug pricing program allows eligible healthcare clinics and hospitals (the covered entities) to purchase outpatient drugs at a 20-50 percent discount to treat low-income, uninsured, or underinsured populations. The program’s forecast growth is expected to benefit Progressive care’s business of providing 340B program services to covered entities through the nationwide expansion of ClearMetrX, its third-party administration and data-management business.

Management Team

Charles M. Fernandez is CEO and Chairman of the Board of Directors of Progressive Care. Mr. Fernandez is also the Executive Chairman and CEO of NextPlat Corp. (NASDAQ: NXPL) and has over 30 years of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. In 2008, he joined Fairholme Capital Management. As president, he co-managed all three Fairholme funds and was commended for bringing in a $2 billion gain for shareholders. Throughout his impressive career in media, pharmaceuticals, healthcare, finance and technology, Mr. Fernandez has participated in more than 100 significant mergers, acquisitions and product development projects. He was the founder, chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK) which was successfully sold to Smartrac, a leading developer, manufacturer and supplier of RFID and Internet of Things (“IoT”) solutions and a unit of Avery Dennison Corporation (NYSE: AVY).

Other top management team members include Chief Operating Officer Birute Norkute, Chief Financial Officer Cecile Munnik, and Pamela Roberts, who serves as the company’s Pharmacist in Charge.

FingerMotion Inc. (RXMD), closed Friday's trading session at $2.99, up 6.4057%, on 756 volume. The average volume for the last 3 months is 307,767 and the stock's 52-week low/high is $2.00/$10.40.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) recently acknowledged an endorsement by leading investment andresearch firm Chardan Capital Research that included a buy ratingfor the company at a price target of $2.00. “We are pleased to beable to share the results of Chardan’s independent analysis of ourcompany’s growth and potential. Our focus on technology-drivensolutions and outstanding customer service has allowed us todifferentiate ourselves in the market, and we will continue tobuild on that success,” a recent article quotes Fr8Tech CEO JavierSelgas as saying. “Fr8Tech has built a suite of technology-basedsolutions to help automate elements of the supply chain in B2Bcross-border and domestic shipping between the United States’primary land-based trading partners with the aim of deliveringoptimal economic performance for the participants. That includes afreight matching platform that is the company’s flagship offering,a cloud-based innovation known as Freight App Inc. (‘Fr8App’) thatenables business owners and fleet managers to monitor and managethe progress of shipments, reduce fuel costs, ensure greater driversafety, and help drivers identify vehicle maintenance needs… InMarch, Fr8Tech announced a new brand under its suite umbrella –Fr8Now, a digital freight-matching platform that offersless-than-truckload (‘LTL’) services in Mexico,” the articlecontinues.

To view the full article, visit

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $1.78, up 2.2989%, on 307,767 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $10.40/$.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Reflex (CSE: RFLX) (OTCQB: RFLXF) (FWB: HF2) is a strategic minerals company focused on locating and developingeconomic properties in the strategic metals and advanced metalsspace. “The company aims to improve domestic specialty mineralinfrastructure efficiencies to meet surging national demand fromNorth American manufacturers, effectively positioning itself as oneof the only North American suppliers of high purity naturalgraphite for hi-tech applications… Processing graphite domesticallyin the U.S. is expected to provide Reflex Advanced Materials acompetitive advantage as manufacturers begin to seek out Americansupply in the face of increased diplomatic tension,” a recentarticle reads. “Its project portfolio includes the Ruby GraphiteDeposit in Montana and the ZigZag Lithium Property in Ontario.Located in a mining-friendly jurisdiction in southwest Montana, theRuby Graphite Deposit is a low-cost, rapid re-entry opportunitythat produced roughly 2,400 tons of graphite from 1902 to 1948.Reflex Advanced Materials holds mining rights for 755 hectares atthe Ruby Graphite Project, with 96 federal lode mining claims.Recent sample assay at 95.8% to 98.4% total carbon… Located in theThunder Bay Mining Division of Ontario, the ZigZag Lithium Propertyconsists of eight mining claims spanning roughly 2,710 hectares.Mineralization at the property, most notably lithium, is based inpegmatite dikes and concentrated in spodumene crystals, which areconsistent throughout the entire unit. Spodumene is readilyobservable in outcrops and in drill cores, with crystal sizesranging from 3-15cm, on average.” To view the full article, visit

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.


Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Friday's trading session at $0.48, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.25/$0.765.

Recent News

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

GeoSolar Technologies (“GST”) is an emerging leader in the green housing space. “Green homes usecarbon-free technology like rooftop solar panels and electric heatpumps rather than those powered by fossil fuels. For full-serviceprovider GST, its SmartGreen(TM) Home system takes decarbonizing ahome to the next level. A whole-house audit is followed byoptimizing insulation, designing and installing a rooftop solarsystem for the home’s electricity, new electric vehicle chargingstation, backup battery power, upgraded windows, solar washer anddryer, smart LED lights and new HVAC (heating, ventilation, airconditioning) system complete with geothermal piping, smart airfiltration and electric heat pump. Geothermal systems use groundsource heat pumps operating with a heat exchanger that, via a loopof pipes run hundreds of feet underground, extracts heat from theground in winter and serves as a heat sink in summer to providecooling,” a recent article explains. “On the point of savings,GeoSolar’s SmartGreen(TM) Homes have scored some of the lowestmarks ever on the HERS (Home Energy Rating System) Index. A typicalhome built around 2006 scores 100 on the HERS Index. The furtherbelow 100, the more efficient the home is (i.e., a score of 70means a home is 30% more efficient). SmartGreen(TM) Homes scorenear zero, meaning they are essentially 100% more efficient than atypical home built in 2006.”

To view the full article, visit

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.


The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.


The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.

Recent News


Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Upstream, a MERJ Exchange market, is making progress toward itsgoal of adding transparency in capital markets using blockchaintechnology with the unveiling of its transparent orderbooks. Thecompany believes that blockchain technology offers the ability tobring unprecedented transparency to trading, and the new orderbooksprovide next-generation features that can create a positive, moreequitable trading market for both issuers and their shareholders. Akey differentiator between Upstream and other markets, thetransparent orderbook provides a platform so that the best bids andoffers are available for everyone to see from an immutable,blockchain-enforced orderbook. Traditional orderbooks presentseveral challenges, including market makers being in charge,secretive stock lending, 0% trading being a fallacy and naked shortselling, which by law is only allowed to be done by market makers.“As a blockchain-powered market, Upstream has a transparentblockchain-backed order book that provides transparency andimmutability, meaning that all transactions and orders are recordedon a ledger that is publicly accessible and cannot be altered,” thecompany stated in the recent blog. “This reduces the risk of marketmanipulation and abuse, as all market participants have access tothe same information about market activity and liquidity. Ourtransparent order book leverages Ethereum smart contracttechnology, which allows for the automation of trading andsettlement processes based on pre-defined rules and conditions. Italso facilitates decentralized trading and asset exchange, whichmeans that traders and investors can exchange assets directly witheach other without the need for a central authority orintermediary.” To view the full blog, visit

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.


Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (, an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News


Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

Coyuchi, the gold standard in sustainable luxury home goods, is best knownfor using 100% organic cotton materials in its textiles. “Thecompany’s sustainably produced products include luxury organicbedding, sheets, towels, apparel, and other home goods that caterspecifically to homes focused on environmental consciousness. Notonly does Coyuchi offer something for every home, but it alsooffers something for every family member, including the newestbundles of joy. Organic cotton is grown naturally and sustainablywithout using herbicides, pesticides or other harmful chemicals,which can irritate a baby’s sensitive skin. Made only with safe,non-toxic materials, Coyuchi’s certified organic products aregentle enough for use from the moment a new baby enters the world.Coyuchi’s line of organic baby products includes blankets, sheetsand other shower gifts that are gentle on the baby and theenvironment,” a recent article explains. “Coyuchi continues pushingthe organic textile market forward through its circular initiativesand supporting cross-industry sustainability advocates… The companywas built on four foundational pillars: protect the planet;innovate circular design; live sustainably; and enrich thecommunity. These principles are integrated into a proven andeffective marketing strategy, earning Coyuchi $33.3 million in netsales during 2021 with a 35% average customer repeat rate.”

To view the full article, visit

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values ( With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through, creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News


Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Silver and gold’s rally may be slowly dying down as buying from hedge funds declines. Last week, prices for both silver and gold hit $26 per ounce and$2,075 per ounce respectively. Despite an increase in sellingpressure, some analysts expect that both precious metals willremain in bullish rallies in the long-term as investors try tosafeguard themselves against worldwide economic uncertainty andrising inflation. The Fed may be considering ending its ongoinghiking cycle after one final rate hike in May. Concurrently,industrial use demand is projected to remain strong through thisyear because of the green-energy shift being adopted globally thatis driving solar power demand.Abrdn’s ETF Investment strategy director Robert Minter stated that metalinvestors needed to be watching silver as the metal had a lot ofpotential and was greatly undervalued. Thus far, silver hasoutperformed gold even as the ratio of gold to silver fell to thelowest level from the start of this year. The latest report from the Commitments of Traders shows that money managers steppedup their speculative total long positions in the Comex silverfutures to 42763 contracts. Simultaneously, short positionsincreased to hit 24973 contracts. Extraction companies such as Eloro Resources Ltd. (TSX: ELO) (OTCQX: ELRRF) are likely to keep an eye on future market movements as they tweaktheir long-term plans in light of the evolving market dynamics.

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Friday's trading session at $2.7, off by 1.7464%, on 12,815 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.09/$3.88031.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

Scientists may have identified a pair of epilepsy syndrome patterns and their link to autoimmune illnesses. The single-center study was carried outbetween January 2016 and December 2020 and involved patients at atertiary epilepsy center. During this period, the researchersgathered data from 242 patients suffering from mesial temporal lobeepilepsy with hippocampal sclerosis and 422 patients with idiopathic generalized epilepsies (IGEs).The researchers observed that, on average, patients who sufferedfrom idiopathic generalized epilepsies were more than a decadeyounger than those with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) They also noted that autoimmune disease prevalence acrossthe sample stood at 5%. The toll taken by autoimmune conditions isrising every year, but there is hope that for-profit companies suchas BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) could soon avail novel immunotherapies to help in the managementof these ailments.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $1.95, off by 2.0101%, on 15,774 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.70/$17.60.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient inSwitzerland as a participant in its ongoing potentially pivotalglobal trial evaluating Berubicin for the treatment of glioblastomamultiforme (“GBM”). “CNS Pharmaceutical’s adaptive, multicenter,open-label, randomized controlled study targets adult patients withrecurrent GBM after failure of standard first-line therapy. Inaddition, the study will also enroll patients who have receivedadditional treatments as part of the first-line therapy inrecognition of the complexity of new agents introduced as acomponent of this therapy. The study will compare Berubicin, anovel anthracycline and the first anthracycline to appear to crossthe blood-brain barrier, to Lomustine, the current standard of care(‘SOC’),” a recent article explains. “In the meantime, beforecompleting assessments on all enrolled participants, CNSPharmaceuticals aims to undertake an interim analysis expectedsometime in the third quarter of 2023. This pre-planned,non-binding futility analysis will include additional evaluation ofsafety and secondary efficacy endpoint. Thus, the latest enrollmentcontinues the company’s progress toward the interim analysis… As aresult of this expanded enrolment, CNS Pharmaceuticals has so faropened over 40 out of 59 clinical trial sites selected acrossSwitzerland, Spain, France, Italy, and the U.S.”

To view the full article, visit

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $1.89, off by 27.8626%, on 3,581,705 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6105/$11.94.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologieswith a focus on monitoring and modulating the immune system, hasentered into a definitive agreement. The company announced aregistered direct offering totaling $1.9 million; the agreement iswith a single healthcare-focused institutional investor andincludes the purchase and sale of 1,585,350 shares of common stock(or common stock equivalents in lieu thereof) at a purchase priceof $1.22 per share (or common stock equivalents in lieu thereof).According to the announcement, a concurrent private placement callsfor the company to also issue unregistered warrants to purchase upto 3,170,700 shares of common stock with an exercise price of $0.86per share; those shares will be immediately exercisable for aperiod of three years following issuance. Gross proceeds from theoffering are projected to be approximately $1.9 million, and thecompany plans to use those proceeds to finance working capital andother general corporate purposes. It is anticipated that theoffering will close on or about April 24, 2023.

To view the full press release, visit

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.


AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.


ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.

Aditxt Inc. (NASDAQ: ADTX), closed Friday's trading session at $0.79, off by 21.7822%, on 1,740,670 volume. The average volume for the last 3 months is 1.741M and the stock's 52-week low/high is $0.75/$28.49.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

You might not get as high off the marijuana you’re buying as you had hoped. A recent study by UNC researchers revealed that most cannabis product labels madeclaims about potency that were higher than what was present in theproducts. The researchers reached these conclusions afterevaluating marijuana samples from multiple Colorado dispensaries.The study’s conclusions highlight the absence of regulations in therapidly growing cannabis market all around the country and raisethe possibility that many consumers are being misled into thinkingtheir purchase will contain more THC, the psychoactive ingredientresponsible for marijuana’s euphoric “high.” For the study, the researchers purchased 23 different varieties of marijuanaflowers from 10 dispensaries in three Colorado cities — GardenCity, Denver, and Fort Collins — and tested the THC levels of eachsample.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Friday's trading session at $0.36, off by 2.834%, on 72,449 volume. The average volume for the last 3 months is 72,449 and the stock's 52-week low/high is $0.2785/$0.8505.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

The multibillion-dollar agricultural industry has been greatly affected by adverse weather conditions, with small marijuana growers feeling the heat most. Almost 3,000small marijuana farmers were recently greatly affected by severeweather, another blow to their businesses, which are alreadygrappling with dropping sales, high taxes and increased competitionfrom larger indoor farms. The state of California has the biggest recreational marijuana market in the country. However, despite working and living in theNorthern California counties of Mendocino, Trinity and Humboldt,cultivators in these parts have struggled since recreationalcannabis was legalized a few years back. The three counties make upthe Emerald Triangle, which comprises communities founded bymarijuana farmers in the ‘60s when individuals began growingmarijuana under the thick canopy of old-growth oak, Douglas fir andredwood trees. Outdoor cultivation has its challenges as thefarmers in the Emerald Triangle will testify, which is why somebusinesses such as Advanced Container Technologies Inc. (OTC: ACTX) have brought innovative products on the market to aid in theindoor cultivation of cannabis and other high-value plants.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.305, off by 4.6875%, on 546 volume. The average volume for the last 3 months is 546 and the stock's 52-week low/high is $0.073/$1.05.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.